arrow&v
arrow&v

PARTICIPATE IN A CLINICAL RESEARCH STUDY

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Chronic kidney disease

GKPTN

A Prospective International Multi-Centre, Observational Cohort Study of Incident and Prevalent Patients Diagnosed with a Kidney Disease

(562) 385-7463

Nina Patel, MD

The George Clinical Institute for Global Health, Australia

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Chronic kidney disease

ZENITH

A Phase 2b Multicentre, Randomised, Double-Blind, Placebo- Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with an eGFF Between 20 and 60 mL/min/1.73 m2

(562) 385-7463

Nina Patel, MD

AstraZeneca

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Chronic kidney disease-related hyperkalemia and metabolic acidosis

NEUTRALIZE

A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium Cyclosilicate (SZC) on Serum Potassium and Serum Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease

(562) 385-7020

Nina Patel, MD

AstraZeneca

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Diabetic foot ulcers

NuShield

A Phase 3, Prospective, Multicenter, Randomized, Controlled Clinical Study of NuShield® and Standard of Care (SOC) Compared to SOC Alone for the Management of Diabetic Foot Ulcers

(562) 385-6201

David Armstrong, DPM

Organogenesis, Inc.

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Epilepsy

Illuminate

A Phase 4, Long-Term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated with Epidiolex (Cannabidiol) Oral Solution

(562) 385-7020

Hui Gong, MD

GW Research LTD

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Epilepsy

RAISE

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IV Ganaxolone in RSE Patients Who Have Failed Benzodiazepines and Two or More Second Line Intravenous Antiepileptic Drugs (AEDs)

(562) 385-7020

Susan Shaw, MD

Marinus Pharmacetuticals

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Polycystic kidney disease

FALCON

A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease

(562) 385-7048

Nina Patel, MD

Reata Pharmaceuticals

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Spinal cord injury-related urinary bladder dysfunction and incontinenece

Bladder Stim

The Effectiveness of Early Sacral Nerve Stimulation in Improving Bladder- Related Complications and Quality of Life after Acute Traumatic Spinal Cord Injury

(562) 385-6201

David Ginsberg, MD

University of Utah

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Stroke rehabilitation

FitMi Plus

FitMi Plus: Smart Functional Modules for Practicing Activities of Daily Living after Stroke

(562) 385-7463

Susan Shaw, MD

Flint Rehab

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Stroke- or TBI-related lower extremity spasticity

ABOLISH

A Phase 4 International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the effectiveness of ABOBONT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort

(562) 385-7048

Ziyad Ayyoub, MD

Ipsen

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Stroke- or TBI-related lower extremity spasticity

PHLEX-LOW

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of a Single-Dose of MYOBLOC in Adult Subjects with Lower Limb Monoplegia or Hemiplegia Spasticity Due to Stroke or TBI, Followed by an Open-Label Extension Safety Study of Multiple Doses

(562) 385-7048

Ziyad Ayyoub, MD

Supernus Pharmaceuticals

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Stroke- or TBI-related upper extremity spasticity

DIRECTION

A Phase 4 Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity

(562) 385-7048

Ziyad Ayyoub, MD

Ipsen

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Stroke- or TBI-related upper extremity spasticity

PHLEX-UP

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Followed by an Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC®

(562) 385-7048

Ziyad Ayyoub, MD

Supernus Pharmaceuticals

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Ulcers of the lower extremity

AnGes

A Phase 2 Double-Blind, Randomized, Placebo-Bontrolled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity

(562) 385-6201

David Armstrong, DPM

AnGes USA, Inc.

Indication:

Trial Name:

Description:

Contact:

Investigator:

Sponsor:

Users of long-term indwelling catheters

Silq

A Phase 4, Prospective, Multi-center, Randomized Study to Assess the Ability of the Silq ClearTract Urinary Catherter to Reduce Biofilm Formation When Compared to Two Types of Commercially Available Foley Catheters (Silver-Coated Latex and Silicone-Coated Latex)

(562) 385-6201

Evgeniy Kreydin, MD

Silq Technologies Corporation